DesRosier Thomas 4
4 · Seres Therapeutics, Inc. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
DesRosier Thomas
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-15+112→ 7,699 total - Sale
Common Stock
2025-11-15$17.30/sh−76$1,315→ 7,623 total - Exercise/Conversion
Restricted Stock Units
2025-11-15−132→ 664 total→ Common Stock (132 underlying) - Exercise/Conversion
Restricted Stock Units
2025-11-15−112→ 1,001 total→ Common Stock (112 underlying) - Exercise/Conversion
Common Stock
2025-11-15+132→ 7,587 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.